ABSTRACT
:: The myocardial consumption of oxygen (ml 100 g' min) was calculated from CBF (ml 100 g min') multiplied by the coronary arteriovenous blood oxygen difference (ml dL p.mol/l) and reduced the 173-estradiol-induced increase in CBF by 55% (Fig. 1A) . The combination of L-NAME and a K channel blocker completely prevented 17f3-estradiol-induced coronary vasodilation (Fig. 1A) . 1 73-Estradiol at I ng kg min1 increased CBF slightly (from 89±2 to 95±2 ml 100 g' min', P=0.08); the increase in CBF with 1713-estradiol at 100 ng kg' min (from 88±2 to 108± 3 ml 100 g min', P<0.01) was similar to that induced at a dose of 10 ng kg min.
Effects of L-NAME, indomethacin, and ibenotoxin on 1713-estradiol-induced coronary vasodilation in the ischemic myocardium Baseline coronary hemodynamic and metabolic parameters did not differ significantly among the van--O---co* (n #{149} #{149} LNME)n.
-0---- ous experimental groups before the onset of coronary hypoperfusion (Table 1 and Table 2 ). Fractional shortening decreased (from 24.8±1.8 to 5.1±0.9%) within 1 mm of the reduction in CPP associated with coronary hypoperfusion and remained constant for 10 mm. CPP was maintained at the initial reduced value throughout the hypoperfusion period. CBF (Fig. 1B) and fractional shortening ( Fig. 1 C) both increased during the infusion of 1713-estradiol for 20 mm; both increases were reduced by L-NAME alone and prevented by the combination of L-NAME and ibeniotoxin.
The lactate extraction ratio and pH MVO2, myocardial oxygen consumption; pH(A) and pH(V), pH of coronary arterial and venous blood, respectively; NE(A) and NE(V), norepinephrine concentration of coronary arterial and venous blood, respectively.
+L-NAME(n=6) +L-NAME epicardial LAD ( Fig. 3B) 
